Table 2.
Intention-to-treat analysis of baseline characteristics
| Characteristic | Neostigmine (n = 40) | Conventional (n = 40) | P value |
|---|---|---|---|
| Age (year) | 46 ± 13 | 49 ± 14 | 0.85 |
| Sex (m/f) | 27/13 | 34/6 | 0.11 |
| Etiology | |||
| Biliary | 12 (30.0%) | 14 (35.0%) | 0.95 |
| Hypertriglyceridemiaa | 21 (52.5%) | 20 (50.0%) | |
| Alcohol excess | 4 (10.0%) | 4 (10.0%) | |
| Idiopathic | 3 (7.5%) | 2 (5.0%) | |
| AP onset to hospital admission (d) | 3 (1–4) | 2 (1–3) | 0.06 |
| AP onset to randomization (d) | 5 (3–7) | 5 (4–6) | 0.55 |
| Comorbidity | |||
| Diabetes mellitus | 3 (7.5%) | 6 (15.0%) | 0.48 |
| Hypertension | 2 (5.0%) | 7 (17.5%) | 0.15 |
| Coronary heart disease | 1 (2.5%) | 0 | 1.00 |
| Chronic renal insufficiency | 0 | 1 (2.5%) | 1.00 |
| Admission clinical severity | |||
| SIRS | 2 (2–3) | 2 (2–3) | 0.70 |
| APACHE II | 9 (7–9) | 9 (7–12) | 0.79 |
| C-reactive protein (mg/L) | 228.6 ± 144.1 | 295.8 ± 125.8 | 0.70 |
| White cell count (× 109/L) | 14.7 ± 5.9 | 14.2 ± 5.6 | 0.45 |
| Procalcitonin (ng/mL) | 1.7 (0.6–13.7) | 2.8 (1.3–6.7) | 0.40 |
| Serum lactate | 2.0 ± 1.3 | 1.7 ± 0.9 | 0.16 |
| Organ failureb | 32 (80.0%) | 27 (67.5%) | 0.31 |
| Single organ failure | |||
| Respiratory | 21 (52.5%) | 17 (42.5%) | 0.50 |
| Renal | 3 (7.5%) | 1 (2.5%) | 0.61 |
| Multiple organ failure | 8 (20.9%) | 9 (22.5%) | 1.00 |
| CTSI within 1 week of AP onsetc | 5 (3–7) | 5 (3–7) | 0.99 |
| ANC | 28 (73.7%) | 26 (76.4%) | 0.63 |
| APFC | 10 (26.3%) | 8 (23.5%) | 0.59 |
| IAH level before randomization, mmHg | 16.3 ± 2.7 | 15.9 ± 2.4 | 0.63 |
| Grade I | 15 (37.5%) | 17 (42.5%) | |
| Grade II | 22 (55.0%) | 21 (52.5%) | |
| Grade III | 3 (7.5%) | 2 (5.0%) | |
| Grade IV | 0 | 0 | |
| ACS | 9 (22.5%) | 6 (15.0%) | 0.56 |
| Use of opioids | 4 (10.0%) | 1 (2.5%) | 0.36 |
| Colonic ileusc,d | 3 (7.9%) | 0 | 0.11 |
| 24 h of defecation (mL) | 450 (10–1050) | 800 (520–990) | 0.14 |
| PCD of ascites | 10 (25.0%) | 6 (15.0%) | 0.40 |
| Admitted to the ICU at randomization | 40 (100%) | 40 (100%) | 1.00 |
ACS abdominal compartment syndrome, AP acute pancreatitis, APACHE II acute physiology and chronic health evaluation II, APFC acute peripancreatic fluid collection, ANC acute necrotic collection, CTSI computed tomography severity index, IAH intra-abdominal hypertension, ICU Intensive Care Unit, PCD percutaneous catheter drainage, RAC Revised Atlanta Classification, SAP severe acute pancreatitis, SIRS systemic inflammatory response syndrome
aDefined as admission serum triglyceride level > 1000 mg/dL and/or lipemic serum after ruling out biliary and alcohol excess etiologies
bPatients with circulatory failure were excluded because neostigmine may affect the circulation
cThere were 38 and 34 cases in the neostigmine group and conventional group, respectively, underwent CT within the first week after AP onset
dOpioids were used in 2 of the 3 patients with colonic ileus